<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201104272982N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2011-10-14</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of intrahemorrhoidal coagulation using 980 nanometer diode LASER with Milligan Morgan hemorrhoidectomy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of intrahemorrhoidal coagulation using 980 nanometer diode LASER with Milligan Morgan hemorrhoidectomy in Shariati hospital in 2010-2012</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2011-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/2897</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>haemorrhoids.</hc_freetext>
      <i_freetext>Intervention 1: control group:  patients undergo general anesthesia with defined protocol and would be placed in lithotomy position. After anoscopy and determining abnormal hemorrhoidal pads, &#13;
they are removed by eliptical incision from anal verge to anorectal ring. Then the base is suture ligated and wound is left open. Patient controlled analgesia device (PCAD)- contains 30 mg morphine sulfate in 30 cc normal saline - is connected in recovery unit and a loading dose is injected. Bolus volume and lock out time would be 1 cc (1 mg morphine) and 8 minutes respectively. Patient are educated before the procedure on how to work with PCAD. One dose of intravenous ceftriaxone and metronidazole given before and continues till 24 hours after surgery. Intervention 2: intervention group: patients undergo general anesthesia with defined protocol and would be placed in lithotomy position. After anoscopy and determining abnormal hemorrhoidal pads, each one would be coagulated using 980 nanometer diode LASER with 15 watts energy and 3 seconds pulses fired in parallel lines, 5 mm apart. No resection is done. Patient controlled analgesia device (PCAD)- contains 30 mg morphine sulfate in 30 cc normal saline - is connected in recovery unit and a loading dose is injected. Bolus volume and lock out time would be 1 cc (1 mg morphine) and 8 minutes respectively. Patient are educated before the procedure on how to work with PCAD. One dose of intravenous ceftriaxone and metronidazole given before and continues till 24 hours after surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zhamak Khorgami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati Hospital, North Kargar Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8490 2450</telephone>
        <email>khorgami@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences - Shariati Hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zhamak Khorgami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati Hospital, North Kargar Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21884902450</telephone>
        <email>khorgami@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences - Shariati hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion Criteria: those with symptomatic hemorrhoids (mainly grade II and III) refractory to medical treatments&#13;
&#13;
Exclusion Criteria: extensive circumferencial grade 4 hemorrhoids, drug-addicted patients, other simultaneous anorectal problems (e.g. fissure)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I84.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified haemorrhoids without complication</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>control group:  patients undergo general anesthesia with defined protocol and would be placed in lithotomy position. After anoscopy and determining abnormal hemorrhoidal pads, &#13;
they are removed by eliptical incision from anal verge to anorectal ring. Then the base is suture ligated and wound is left open. Patient controlled analgesia device (PCAD)- contains 30 mg morphine sulfate in 30 cc normal saline - is connected in recovery unit and a loading dose is injected. Bolus volume and lock out time would be 1 cc (1 mg morphine) and 8 minutes respectively. Patient are educated before the procedure on how to work with PCAD. One dose of intravenous ceftriaxone and metronidazole given before and continues till 24 hours after surgery.</i_keyword>
      <i_keyword>intervention group: patients undergo general anesthesia with defined protocol and would be placed in lithotomy position. After anoscopy and determining abnormal hemorrhoidal pads, each one would be coagulated using 980 nanometer diode LASER with 15 watts energy and 3 seconds pulses fired in parallel lines, 5 mm apart. No resection is done. Patient controlled analgesia device (PCAD)- contains 30 mg morphine sulfate in 30 cc normal saline - is connected in recovery unit and a loading dose is injected. Bolus volume and lock out time would be 1 cc (1 mg morphine) and 8 minutes respectively. Patient are educated before the procedure on how to work with PCAD. One dose of intravenous ceftriaxone and metronidazole given before and continues till 24 hours after surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postoperative narcotic usage. Timepoint: continuous till time of discharge. Method of measurement: Patient controlled analgesia device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Postoperative urinary retention. Timepoint: At the time of discharge. Method of measurement: History taking.</sec_outcome>
      <sec_outcome>Postoperative bleeding. Timepoint: At the time of discharge. Method of measurement: History taking and clinical records.</sec_outcome>
      <sec_outcome>Operation time. Timepoint: At the end of surgery. Method of measurement: from start (after prep and drep) till end (before dressing).</sec_outcome>
      <sec_outcome>Bleeding during surgery. Timepoint: At the end of surgery. Method of measurement: based on the number of wet gauzes.</sec_outcome>
      <sec_outcome>Postoperative pain. Timepoint: 6 hour interval. Method of measurement: Visual analogue scale.</sec_outcome>
      <sec_outcome>Hospital stay. Timepoint: At the time of discharge. Method of measurement: based on medical reocords.</sec_outcome>
      <sec_outcome>Recovery of treated hemorrhoids. Timepoint: 3 months after surgery. Method of measurement: Physical examination.</sec_outcome>
      <sec_outcome>Surgical site infection. Timepoint: At the time of discharge and one week later. Method of measurement: Physical examination.</sec_outcome>
      <sec_outcome>Recovery of symptoms. Timepoint: 3 months after surgery. Method of measurement: History taking.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-01-12</approval_date>
        <contact_name>Tehran University of Medical Sciences</contact_name>
        <contact_address>Central building, Qhods avenue Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
